文献速递眼底病与葡萄膜炎

美国新生血管性年龄相关性黄斑变性VEGF抑制剂治疗的成本效益分析

A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States.
PubMed 文献 · Am J Ophthalmol · 2020-07-16

基于2018年美国168,400例新发新生血管性年龄相关性黄斑变性(NVAMD)患者,比较贝伐珠单抗、雷珠单抗和阿柏西普单药治疗11年的社会成本效益。贝伐珠单抗治疗成本14,772美元并带来357,680美元社会净回报(ROI 2,421%),雷珠单抗成本106,582美元回报265,870美元(ROI 249%),阿柏西普成本61,811美元回报310,611美元(ROI 503%)。

要点

  • 贝伐珠单抗11年治疗成本14,772美元,社会净回报357,680美元,ROI 2,421%。
  • 雷珠单抗与阿柏西普的ROI分别为249%和503%,均低于贝伐珠单抗。

核心结论

  • 三种VEGF抑制剂单药治疗NVAMD均产生可观财务回报并增加国家财富,贝伐珠单抗的社会回报率最高。

研究设计与样本

  • 成本效益分析,使用已发表临床试验数据和医疗保险数据,基于价值医学中心方法。
  • 患者人群为2018年美国估计168,400例新发NVAMD患者,使用2018年美国实际美元。

主要发现

  • 贝伐珠单抗11年个体治疗成本14,772美元,社会净回报357,680美元(ROI 2,421%)。
  • 雷珠单抗治疗成本106,582美元,社会回报265,870美元(ROI 249%)。
  • 阿柏西普治疗成本61,811美元,社会回报310,611美元(ROI 503%)。

临床怎么用

  • 在NVAMD抗VEGF治疗选择中,贝伐珠单抗具有最高的社会投资回报率,可优先考虑以节约医疗资源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To perform a societal cost-benefit analysis comparing intravitreal bevacizumab (Avastin), ranibizumab (Lucentis), and aflibercept (Eylea) monotherapies for treating neovascular age-related macular degeneration (NVAMD). DESIGN: Cost-benefit analysis. METHODS: Center for Value-Based Medicine using published clinical trial and Medicare data. PATIENT POPULATION: 168,400 estimated 2018 U.S. patients with new-onset NVAMD. Procedure(s): cost-benefit analysis using 2018 U.S. real dollars. OUTCOME MEASUREMENTS: 11-year direct ophthalmic medical costs expended for bevacizumab, ranibizumab, and aflibercept monotherapies were compared with ophthalmic and nonophthalmic direct medical, direct nonmedical, and indirect medical (productivity) costs saved by the therapies. RESULTS: Bevacizumab monotherapy had an individual, 11-year $14,772 treatment cost and net $357,680 societal return (11-year 2,421% return on investment [ROI]). Ranibizumab therapy cost $106,582 and returned $265,870 to society (249% ROI), whereas aflibercept treatment cost $61,811 and returned $310,611 to society (503% ROI). The 2018 NVAMD overall treatment cohort, 11-year net societal gain was $28.5 billion to patients and insurers, with $24.2 billion (84.9%) coming from bevacizumab therapy, $0.7 billion (2.5%) from ranibizumab therapy, and $3.6 billion (12.6%) from aflibercept therapy. Substituting bevacizumab for ranibizumab and aflibercept in the 2018 new-onset NVAMD patients would save an estimated $1.343 billion over 11 years. Vascular endothelial growth factor-inhibitor (VEGF-I) therapy in 2018 should contribute $12.2 billion to the Gross Domestic Product over 11 years. Late treatment would decrease this by 78% to $2.7 billion. CONCLUSIONS: Intravitreal NVAMD bevacizumab, ranibizumab and aflibercept monotherapies accrue considerable financial, ROIs to patients and insurers as they increase national wealth.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Brown GC, Brown MM, Rapuano SB, et al. A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States. Am J Ophthalmol. 2020. PMID: 32681907. doi:10.1016/j.ajo.2020.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。